<DOC>
	<DOCNO>NCT00187174</DOCNO>
	<brief_summary>Patients recurrent refractory solid tumor brain tumor unresponsive conventional therapy , know effective therapy , treat . Experiments laboratory show experimental drug RAD001C ( RAD001 , Everolimus ) prevent cell multiply . RAD001 test disease cancer , excessive cell multiplication need stop . The drug test adult cancer patient well tolerated subject study . It experimental , therefore , available clinical trial .</brief_summary>
	<brief_title>Everolimus Treating Pediatric Patients With Recurrent Refractory Tumors</brief_title>
	<detailed_description>Although Phase II portion study plan , never initiate .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Adequate performance status Adequate bone marrow , kidney , heart , liver function Must receive concomitant anticancer treatment Must pregnant</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Brain tumor</keyword>
	<keyword>Soft Tissue Sarcomas</keyword>
	<keyword>Refractory solid tumor</keyword>
	<keyword>Recurrent Refractory Rhabdomyosarcomatous Soft Tissue Non-Rhabdomyosarcoma Soft Tissue Sarcomas</keyword>
</DOC>